EP1509213A2 - Acetamides and benzamides that are useful in treating sexual dysfunction - Google Patents

Acetamides and benzamides that are useful in treating sexual dysfunction

Info

Publication number
EP1509213A2
EP1509213A2 EP03755402A EP03755402A EP1509213A2 EP 1509213 A2 EP1509213 A2 EP 1509213A2 EP 03755402 A EP03755402 A EP 03755402A EP 03755402 A EP03755402 A EP 03755402A EP 1509213 A2 EP1509213 A2 EP 1509213A2
Authority
EP
European Patent Office
Prior art keywords
acetamide
hydrogen
methyl
cyano
pyridinyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP03755402A
Other languages
German (de)
English (en)
French (fr)
Inventor
Pramila A. Bhatia
Jerome F. Daanen
Ahmed A. Hakeem
Teodozyj Kolasa
Mark A. Matulenko
Kathleen H. Mortell
Meena V. Patel
Andrew O. Stewart
Xueqing Wang
Zhiren Xia
Henry Q. Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/154,373 external-priority patent/US20030232836A1/en
Priority claimed from US10/425,152 external-priority patent/US20040029887A1/en
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Priority claimed from PCT/US2003/015868 external-priority patent/WO2003099266A2/en
Publication of EP1509213A2 publication Critical patent/EP1509213A2/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings

Definitions

  • the present invention relates to the use of acetamides and benzamides and compositions containing these compounds for the treatment of sexual dysfunction.
  • DA dopamine
  • PAG periaqueductal gray
  • PAG periaqueductal gray
  • PAG periaqueductal gray
  • PNN paraventricular nucleus
  • DA receptor agonists like apomorphine ((6aR) 5,6,6a,7- tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,l l-diol), quinpirole and (-) 3-(3- hydroxyphenyl)-N-propylpiperidine (3-PPP) facilitate penile erection in rats, an effect blocked by haloperidol, a central DA antagonist.
  • DA receptor agonists like apomorphine ((6aR) 5,6,6a,7- tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,l l-diol), quinpirole and (-) 3-(3- hydroxyphenyl)-N-propylpiperidine (3-PPP) facilitate penile erection in rats, an effect blocked by haloperidol, a central DA antagonist.
  • domperidone a peripheral DA antagonist
  • Clinical data also indicates that DA systems in the CNS play a role on the regulation of male sexual behavior as indicated by the sexual stimulatory effect of L-dopa in Parkinson's patients and by the pro-erectile effect of apomorphine in humans.
  • DA receptors belong to a superfamily of protein receptors that signal across the cell membrane by coupling to intracellular GTP-binding proteins.
  • G proteins include Gs, Gq and Gi
  • the Di-like receptors include Di and D 5 .
  • the D 2 -like receptors include D 2 , D 3 and D 4 .
  • the Di-like family receptor subtypes are G s -coupled and can activate adenylate cyclase.
  • the D 2 -like family receptor subtypes are Gj-coupled and they increase intracellular calcium level and inhibit adenylate cyclase.
  • the Di-like family members are G s -coupled receptors that can activate adenylate cyclase.
  • the Di receptor is the most abundant and widespread DA receptor in the CNS both by mRNA expression and by immunohistochemical studies. It is found in the striatum, nucleus accumbens and olfactory tubercle as well as the limbic system, hypothalamus and thalamus.
  • the Di receptor expression has been reported in the heart and kidney, and despite that the function of these peripheral Di receptors remains to be clarified, its role on the control of hemodynamic variables has been confirmed.
  • the D 5 receptor while having a higher affinity for DA than the Di receptor, is sparsely distributed in the CNS with no evidence of expression outside the CNS. .
  • the D 2 -like family members are Gi coupled receptors that inhibit adenylate cyclase and increase intracellular calcium levels.
  • the D 2 receptor is the most abundant of the D 2 -like receptors and is located in brain areas such as the striatum and substantia nigra, and in peripheral areas such as the heart, pituitary gland and kidney.
  • the D 3 receptor is found abundantly in the islands of Calleja with distinct cluster populations in the ventral striatum/nucleus accumbens regions, olfactory tubercle, dendate gyrus and striatal cortex.
  • D 4 receptor has been documented by in situ RNA hybridization and immunohistochemical studies. Recently, studies revealed that D 4 expression is highest in the entorhinal cortex, lateral septal nucleus, hippocampus and the medial preoptic area of the hypothalamus. Localization of D 4 is distinct from the distribution of D 2 in the brain, as D 2 receptors are most abundant in striatal areas.
  • the expression of D receptors in the MPOA of the hypothalamus is of importance to the facilitation of penile erection in view of the role of the hypothalamus as an area of integration between the cortex and the spinal pathways. The participation of D 4 receptors in other CNS regions, thalamic, subthalamic and spinal can not be excluded.
  • the present invention identifies a therapeutic use for acetamides and benzamides of formula (I) in the treatment of sexual dysfunction in mammals. More specifically, these compounds are useful in the treatment of sexual dysfunction including, but not limited to, male erectile dysfunction (MED).
  • MED male erectile dysfunction
  • the present invention relates to a method of treating sexual dysfunction in a mammal, in particular humans, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I)
  • A is aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;
  • L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or-C(S)N(R 7 )- wherein the left end of said -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- is attached to A and the right end is attached to D;
  • D is alkylene, fluoroalkylene, or hydroxyalkylene
  • Z is N, C or CR B ;
  • R A is hydrogen or alkyl
  • R B is hydrogen, alkyl, or halogen
  • — is a bond when Z is C and — is absent when Z is N or CR B ;
  • Ri, R 2 , R 3 , R 4 and R5 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )sulfonyl;
  • Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
  • Z 3 and Z 4 are each independently hydrogen, alkyl, aryl, or arylalkyl
  • Y is C(R ) or N
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl.
  • the present invention relates to a method of treating sexual dysfunction in a mammal, in particular humans, comprising administering to the mammal a therapeutically effective amount of a compound of formula (I)
  • A is aryl, arylalkyl, cycloalkyl, cycloalkylalkyl, heterocycle, or heterocyclealkyl;
  • L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or-C(S)N(R 7 )- wherein the left end of said -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- is attached to A and the right end is attached to D;
  • D is alkylene, fluoroalkylene, or hydroxyalkylene
  • Z is N, C or CR B ;
  • RA is hydrogen or alkyl
  • RB is hydrogen, alkyl, or halogen
  • — is a bond when Z is C and — is absent when Z is N or CR B ;
  • Ri, R 2 , R 3 , R 4 and R 5 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfmyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z )sulfonyl;
  • Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
  • Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
  • X is N(R 6 ), O or S
  • Y is C(R 4 ) or N
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R l3 R 2 , R 3 , R 4 , R 5 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • R 4 and R 5 are hydrogen;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Rj is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen,
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
  • NZ 3 Z 4 carbonyl
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(S)-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z 4 carbonyl
  • R 2 and Rt are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R )C(O)-; and R 7 and RA are as defined in formual (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH(CH 3 )-;
  • L is -N(R 7 )C(O)-; and
  • R and R A are as defined in formual (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is z is N . ... is absent .
  • L is _N(R 7 )C(O)-; and D, R, , R 2 , R 3 ,
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyaiio, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R )C(O)-; and R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is Z is N; — is absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , i, R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 , R 3 , and R 4 are hydrogen; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)- ; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R 2 N ' ⁇ / R 3
  • a 4 - ⁇ j ⁇ an( j j ⁇ are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is - N(R )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • L is -N(R 7 )C(O)-; and D, X, Y, R 2 , R 3 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is
  • R_, R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle; B is
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • N . ... is absent .
  • D is . CH .
  • L is -N(R 7 )C(O)-; and R, , R 2 , R 3 , R t , R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • D is _ C H(CH 3 )-; L is -N(R 7 )C(O)-; and R,, R 2 , R 3 , R A , R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is the group consisting of hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and RA are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is the group consisting of hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R 4 are hydrogen; R is hydrogen or hydroxy;
  • Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • R u R 2 , R 3 , R A , R I , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and R are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is .
  • NZ 3 Z 4 carbonyl
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl; B is
  • z is N; — is absent; L is -N(R 7 )C(O)-; and D, Ri, R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z 4 carbonyl
  • R 2 and R 4 are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
  • NZ3Z 4 carbonyl; R and R are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, Ri, R 2 , R 3 , R 4 , R 5 , R 7 , R B , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, and -NZ[Z 2 ; B is
  • Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; Rj and R 5 are hydrogen; Z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is hydrogen; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ_Z 2 ; B is is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • NZ ⁇ Z 2 , or (NZ 3 Z 4 )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is CR B ⁇ — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is halogen wherein a preferred halogen is -F; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R l is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • 4 and R 5 are hydrogen;
  • Z is CR B ; — is absent;
  • D is -CH(CH 3 )-;
  • L is -N(R 7 )C(O)-;
  • R B is hydrogen; and
  • R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • Z is CR B ; — is absent; L is -N(R 7 )C(O)-; R B is hydrogen; and D, R u R 2 , R 3 ,
  • R 4 , R 7) and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; — is absent; D is -CH 2 -; L is -N(R 7 )
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is CR B ;
  • — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(S)-;
  • R B is hydrogen; and R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R B is hydrogen; and R , R B , and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • RA, R ⁇ , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • R] is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CRB; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-;
  • RB is hydrogen; and
  • R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
  • X is N(Rs), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R B is hydrogen; and R_, R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is ; X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R B is hydrogen; and Re, R 7 and R A are as defined in formula (I) wherein A is aryl wherein
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • z is CR B ; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R 2 , R 3 , and j are hydrogen; R B is hydrogen; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, R,, R 2 , R 3 , 4 , R 7 , R B , and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
  • R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R ls R 2 , R 3) and RA are hydrogen; Z is CR B ; RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
  • R 1 ⁇ R 2 , R 3 , and RA are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
  • R ⁇ , R 2 , R 3 , and RA are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl; B is Ri, R 2 , R3, and j are hydrogen; Z is CRB; RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
  • A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH-indenyl
  • B Ri, R 2 , R3, and j are hydrogen
  • Z is CRB
  • RB is hydrogen
  • — is absent
  • D is -CH 2 -
  • L is -N(R 7 )C(O)-
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • L is -N(R 7 )C(O)-; and
  • D, R u R 2 , R 3 , R A , R 7 , and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • RB is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and RA are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R A are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -N(R )C(O)-; and
  • R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • R u R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; RB is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
  • R ! is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • RA and R 5 are hydrogen;
  • Z is C; — is a bond;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; R ! is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • NZ ⁇ Z 2 , or (NZ 3 Z )alkyl R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; RA and R 5 are hydrogen; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R z is C; — is a bond; L is -N(R 7 )C(O)-; and D, R x , R 2 ,R 3 , R 4 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R ⁇ i s hydroge , alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl; R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-;
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Z is C; — is a bond; L is -N(R 7 )C(O)-; and D, R b R 2 , R 3 , Rt, R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • z ig c . __. is a bond . L . is . N ( R7 ) (o). ; and D, X, Y, R 2 , R 3 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • X is N(R 6 ), O, or S; Y is C(R 4 ); R 2 and R 3 are hydrogen; R 4 is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 6 , R , and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; X is N(R 6 ), O, or S; Y is C(R- t ); R 2 and R 3 are hydrogen; RA is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • R u R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and R are hydrogen; R3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • R s hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R l s R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R ⁇ is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • R and R 5 are hydrogen;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -C(0)N(R 7 )-; and
  • R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • R 4 and R 5 are hydrogen;
  • Z is N; — is absent;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 ; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -C(O)N(R 7 )-; and
  • R and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
  • R! is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z 4 carbonyl
  • R and R4 are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 CH 2 -; L is -C(O)N(R )-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • L is -C(0)N(R 7 ; and D, R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 , R 3 , and 4 are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • Z is N; — is absent; L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 , R , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and R_ % are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R and R A are as defined as in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • Z is CR B ;
  • RB is hydrogen;
  • — v is absent;
  • L is -C(O)N(R 7 )-; and D, R R 2 , R 3 ,
  • RA, R 5 , R7, and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • NZ]Z 2 or (NZ 3 Z )alkyl
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy
  • R 3 is hydrogen or hydroxy
  • R 4 and R 5 are hydrogen
  • Z is CR B
  • R B is hydrogen
  • — is absent
  • D is -CH 2 -
  • L is -C(O)N(R 7 )-
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, -
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • j and R 5 are hydrogen;
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R ⁇ is hydrogen; — is absent; L is -C(O)N(R 7 )-; and D, R 1; R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and RA are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • D is -CH(CH )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkeriyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Z is CR B ;
  • R B is hydrogen; — is absent; D is - CH 2 -; L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
  • R B is hydrogen; — is absent; D is CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is Z is CR B ; R B is hydrogen; — is absent; L is -C(O)N(R 7 )-; and D, R R 2 , R 3 , R , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and RA are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is ; Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent
  • B is ;
  • Ri, R 2 , R 3 , and R A are hydrogen;
  • Z is CR B ;
  • R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a preferred alkyl substituent is methyl; B is
  • Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
  • Ri, R 2 , R 3 , and R are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(S)N(R 7 )-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and RA are hydrogen; Z is CRB; RB is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
  • Ri, R 2 , R 3 , and R A are hydrogen; Z is CRB; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • L is -C(O)N(R 7 )-; and
  • D, Ri, R 2 , R 3 , R t , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is , benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is ; Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl,
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined on formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • L is -C(O)N(R 7 )-; and D, R ls R 2 , R 3 ,
  • RA, R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is ; Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and I are hydrogen; R 3 is hydrogen or hydroxy; Z is CRB; RB is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl,
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R R 2 , R 3 , RA, R 5 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is ; Ri is hydrogen, alkoxy, alkyl, alkylthio, cyano, halogen, hydroxy, nitro, - NZ ⁇ Z 2 , or (NZ 3 Z )alkyl; R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy; R 3 is hydrogen or hydroxy; R 4 and R 5 are hydrogen; Z is C;
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 is hydrogen, alkoxy, cyano, halogen, or hydroxy;
  • R 3 is hydrogen or hydroxy;
  • R A and R 5 are hydrogen;
  • Z is C; — is a bond;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • R R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl; B is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R$, R 7 , and RA are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl; B is
  • Z is C; — is a bond; L is -C(O)N(R 7 )-; and D, R b R 2 , R 3 , R A , R 7 , and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Rl ig hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and RA are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH 2 -;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is R 2
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and RA are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (I).
  • the present invention relates to compounds of formula (II)
  • A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
  • L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
  • D is alkylene, fluoroalkylene, or hydroxyalkylene
  • Z is selected from N, C or CR B ;
  • R A is hydrogen or alkyl
  • R B is hydrogen, alkyl, or halogen
  • — is a bond when Z is C and — is absent when Z is N or CRB;
  • Ri, R 2 , R 3 , and R ⁇ are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )suIfonyl;
  • Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
  • Z 3 and Z 4 are each independently hydrogen, alkyl, aryl, or arylalkyl
  • X is N(R 6 ), O, or S
  • Y is C(R 4 ) orN
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl.
  • compounds of formula (II) are disclosed wherein A is aryl; B is
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 arid RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
  • R . i hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is from hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and ; are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(S)-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is
  • N; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 7 and RA are as defined in formula
  • compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is Z is N; — is absent; L is -N(R 7 )C(O)-; and D, Rj , R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • R t is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined on formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • NZ 3 Z carbonyl
  • R 2 and R 4 are hydrogen; R3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R and RA are as defined on formula (II).
  • Z is N; — is absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents 1 independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 7 and R are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ[Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is N; — is absent; D is
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(Re), O, or S; Y is N; Z is N; — is absent; D is
  • R 6 , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZiZ 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is arylalkyl wherein the aryl of arylalkyl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected frorh alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZiZ 2 ;
  • B is -
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH(CH 3 )-;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula (II).
  • R u R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
  • B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and Rt are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • RB is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )carbonyl; R 2 and t are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R )C(S)-; and R and RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • R t is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is Z is CR B ; — is absent; L is -N(R 7 )C(O)-; R B is hydrogen; and D, Ri, R 2; R 3 ,
  • RA, R 7 , and RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • Y Rs ; Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, X, Y, R 2 , R 3 , R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
  • X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; R B is hydrogen;
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • X is N(R 6 ), O, or S; Y is N; R 2 and R 3 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; and R 6 , R 7 and RA are as defined in formula (II).
  • z is CR ⁇ . ... ig absent; L is -N(R 7 )C(O)-; and D, R 2 , R 3 , R+, R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
  • z is CR B ;
  • R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; R 2 , R 3 , and R are hydrogen; and R 7 and RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • D is -CH(CH 3 )-; L is -N(R 7 )C(O)-; R 2 , R 3 , and 4 are hydrogen; and R 7 and R A are as defined in formula (II).
  • R b R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri, R 2 , R 3 , and RA are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are hydrogen.
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is tetrahydronaphthalenyl or 2,3-dihydro-lH- indenyl; B is
  • Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is
  • R 7 and R A are hydrogen.
  • compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is Z is CR B ;
  • R B is hydrogen; — is absent;
  • L is -N(R 7 )C(O)-;
  • D, R h R 2 , R 3 , R t , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and Rt are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined on formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and R A are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • RB is hydrogen; — is absent;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and RA are as defined on formula (II).
  • compounds of formula (II) wherein A is cycloalkyl; B is Z is CR B ; — is absent; L is -N(R 7 )C(O)-; and D, R] , R 2 , R 3 , R 4 , R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or _>
  • NZ 3 Z carbonyl
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -N(R 7 )C(O)-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are . disclosed wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and * are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • RB is hydrogen;
  • — is absent;
  • D is -CH(CH 3 )-;
  • L is -N(R 7 )C(O)-; and
  • R and RA are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
  • B is Rj is hydrogen, alkyl, cyano, halolalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ3Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH 2 -;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pyrrolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • z is C; — is a bond; L is -N(R 7 )C(O)-; R B is hydrogen; and D, R h R 2 , R 3 , A , R ⁇ , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -N(R 7 )C(O)-; RB is hydrogen; and R 7 and R A are as defined on formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • X is N(R 6 ), O, or S
  • Y is C(R 4 );
  • R 2 and R 3 are hydrogen;
  • R 4 is hydrogen, alkyl, or cyano;
  • Re, R 7 , and R are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • X is N(R 6 ), O, or S; Y is C(R 4 ); R 2 and R 3 are hydrogen; t is hydrogen, alkyl, or cyano; Z is C; — is a bond; D is -CH(CH 3 )-; L is -N(R )C(O)-; and R 6 , R 7 , and R A are as defined in formula (II).
  • R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH(CH 3 )-;
  • L is -N(R 7 )C(O)-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl; B is ; Z is N; — is absent; L is -C(O)N(R 7 )-; and D, R h R 2 , R 3 , R 4 , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and RA are hydrogen; R 3 is hydrogen or hydroxy; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and RA are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ 1 Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 , R 3 , and R A are hydrogen; Z is N; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )- ; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 , R 3 , and A are hydrogen; Z is N; — is absent; D is -CH(CH 3 )-; L is - C(O)N(R )-; and R 7 and R A are as defined in formula (II).
  • z is N . ... i s absen t; L is -C(O)N(R 7 )-; and D, Ri , R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
  • A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl;
  • B is Rj j ., hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and * are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH 2 -;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is N; — is absent;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (II).
  • Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, R ⁇ , R z , R 3 , R A , R ⁇ , R B , and R A are as defined in formula (Et).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is ; Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl; R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl; B is Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 , R A , R 7 , R B , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , and R A are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R )-; and R and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • R 7 and R A are hydrogen.
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent; B is
  • R 2 , R 3 , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
  • R B is hydrogen; — is absent; D is -CH2-; L is -C(O)N(R 7 )-; and R 7 and R A are hydrogen.
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 1 alkyl substituent wherein a prefened alkyl substituent is methyl; B is
  • R 7 and R A are hydrogen.
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, allcythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R b R 2 , R , and R 4 are hydrogen; Z is CR B ; R B is hydrogen; — is absent; D is -CH(CH 3 )-; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is ;
  • Z is CR B ;
  • R B is hydrogen; — is absent;
  • L is -C(O)N(R 7 )-; and D, Ri, R 2 , R 3 ,
  • R4, R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z )carbonyl;
  • R 2 and * are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined on formula (II).
  • compounds of formula (II) are disclosed wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, pyrazolyl, pyridinyl, or thienyl wherein the heterocycle is independently substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is
  • Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH 2 -;
  • L is -C(O)N(R )-; and
  • R 7 and R A are as defined on formula (II).
  • compounds of formula (II) wherein A is cycloalkyl; B is Z is CR B ; — is absent; L is -C(O)N(R 7 )-; and D, R 1; R 2 , R 3 , R 4 , R 7 , R B , and
  • R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • R 2 and A are hydrogen; R 3 is hydrogen or hydroxy; Z is CR B ; R B is hydrogen; — is absent; D is -CH 2 -; L is -C(O)N(R 7 )-; and R and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is CR B ;
  • R B is hydrogen;
  • — is absent;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R and R A are as defined in formula (II).
  • z is C; — is a bond; L is -C(O)N(R 7 )-; and D, Ri , R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
  • B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1 , 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R and R A are hydrogen;
  • R3 is hydrogen or hydroxy;
  • Z is C;
  • — is a bond;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 , R 3 , and R A axe hydrogen;
  • Z is C;
  • — is a bond;
  • D is -CH 2 -;
  • L is -C(O)N(R 7 )-; and
  • R and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is naphthyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is l 2
  • Rj is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is C; — is a bond;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl; B is
  • Z is C; — is a bond; L is -C(O)N(R 7 )-; and D, X, Y, R 2 , R 3 , R 7 and R A are as defined in formula (II).
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(Rg), O, or S; Y is N; Z is C; — is a bond; D is
  • compounds of formula (II) are disclosed wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; X is N(R 6 ), O, or S; Y is N; Z is C; — is a bond; D is
  • L is _ C (0)N(R 7 )-; and D, R ls R 2 , R 3 , R A , R 7 , and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is l 2
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and A are hydrogen; R 3 is hydrogen or hydroxy; Z is C; — is a bond; D is -CH 2 -; L is -C(O)N(R 7 )-; and R 7 and R A are as defined in formula (II).
  • compounds of formula (II) wherein A is cycloalkyl wherein the cycloalkyl is cyclohexyl or adamantyl; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R A are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Z is C;
  • — is a bond;
  • D is -CH(CH 3 )-;
  • L is -C(O)N(R 7 )-; and
  • R 7 and R A are as defined in formula (11).
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridimum N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridimum N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)ammo]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such treatment a therapeutically effective amount of 2-(l- ⁇ [(3- methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4- piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridir_ium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of 2-(l- ⁇ [(3-methylbenzoyl)ammo]methyl ⁇ -4-piperidinyl)pyridinium N- oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such freatment a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
  • the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such freatment a therapeutically effective amount of 2-(l- ⁇ [(3- methylbenzoyl)amino]methyl ⁇ -4-piperidinyl)pyridinium N-oxide or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
  • the present invention relates to compounds of formula (III)
  • Xi is a bond or CR B RC!
  • X 2 is a bond or CRDRE . provided that when Xi is a bond, then X 2 is C D E; further provided that when X 2 is bond, then Xi is CR ⁇ Rc;
  • A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
  • L is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
  • L 2 is a bond or alkylene
  • D is alkylene, fluoroalkylene, or hydroxyalkylene
  • RA, RB, R C , RD, and R E are independently hydrogen or alkyl
  • Ri, R 2 , R 3 , and R 4 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfmyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z 4 )sulfonyl;
  • Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
  • Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
  • X is N(Re), O, or S
  • Y is C(R 4 ) or ;
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl.
  • the present invention relates to compounds of formula (III) wherein A is aryl; B is
  • X ⁇ is CR ⁇ Rc .
  • ⁇ 2 is CR D R E ;
  • L is -N(R 7 )C(O)-; and
  • R A , R B , R C , R D , and R E are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents indpendently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ;
  • B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ Z 4 )alkyl, or
  • R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Xi is CR B Rc; X 2 is CRDRE; D is -CH 2 -; L 2 is a bond; and L is -N(R 7 )C(O)-; and R A , R B , Re, RD, RE, RI, R2, R3, R_ t , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy;
  • X] is CR B Rc;
  • X 2 is CR D R E.
  • D is -CH -;
  • L 2 is a bond;
  • L is -N(R 7 )C(O)-; and
  • RA, R B , RC, R D , R E , and R are hydrogen.
  • the present invention relates to compounds of formula (III) wherein A is heterocycle; B is
  • X ! is CR B R C.
  • X2 is CR D R E ;
  • L is -N(R 7 )C(O)-; and D, L 2 , X, Y, R A , R B , Rc, R D ,
  • R E , R 2 , R 3 , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl,
  • R 2 and R 3 are hydrogen; Xi is CR B Rc; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R A , R B , Rc, RD, RE, R2, R3, and R 7 are hydrogen; and R 6 is hydrogen or alkyl wherein a prefened alkyl is methyl.
  • the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
  • X is CR B Rc
  • X2 is CR D R E
  • X is N(R 6 ), 0, or S
  • Y is
  • the present invention relates to compounds of formula (III) wherein A is aryl; B is
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZjZ 2 ; B is
  • R ⁇ is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z 4 )alkyl, or
  • R 2 and R A are hydrogen; R 3 is hydrogen or hydroxy; Xi is a bond; X 2 is CRDR E ; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R D , and R E are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZjZ 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z )alkyl, or (NZ 3 Z 4 )carbonyl;
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Xi is a bond;
  • X 2 is C D R E ;
  • D is -CH2-;
  • L 2 is a bond;
  • L is -N(R 7 )C(O)-;
  • R 7 , RA, R D , and RE are hydrogen.
  • the present invention relates to compounds of formula (III) wherein A is heterocycle;
  • B is
  • R 3 , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro;
  • B is
  • R 2 and R 3 are hydrogen; X! is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 6 , R A , R D , R E , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (111) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
  • R 2 and R 3 are hydrogen; X] is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
  • the present invention relates to compounds of formula (III) wherein A is aryl; B is X 2 is CR D R E ; L is -N(R 7 )C(O)-; and D, L 2 , X, Y, R A , R D , R E , 2 , R 3 , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D RE; X is N(Re), O, or S; Y is C(R- ; D is -CH 2 -; L 2 is a bond; L is -N(R )C(O)-; * is hydrogen, alkyl, or cyano; and R ⁇ , R A , R D , R E , R A , and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ]Z 2 ; B is
  • R 2 and R 3 are hydrogen; X! is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
  • R E , R A , and R 7 are hydrogen; and Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
  • the present invention relates to compounds of formula (III) wherein A is aryl; B is
  • Xj is CRBRC; X2 is a bond; L is -N(R 7 )C(O)-; and L 2 , D, R h R 2 , R 3 , R 4 , R 5 ,
  • R 7 , R A , R B , and Rc are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri, R 2 , R 3 , RA, and R 5 are hydrogen; Xi is CRBRC; X 2 is a bond; D is -CH 2 -;
  • L 2 is -CH 2 -; L is -N(R 7 )C(O)-; and R B , Rc, and R 7 are as defined in formula (III).
  • the present invention relates to compounds of formula (III) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ]Z 2 ; B is
  • Ri, R 2 , R 3 , RA, and R 5 are hydrogen; Xi is CR B Rc; X 2 is a bond; D is -CH 2 -;
  • L 2 is -CH 2 -; L is -N(R )C(O)-; and R B , Rc and R 7 are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to said mammal in need of such freatment a therapeutically effective amount of a compound of formula (IV)
  • Xi is a bond or CRBRC
  • X 2 is a bond or CRDRE; provided that when Xi is a bond, then X 2 is CRDRE; further provided that when X 2 is bond, then Xi is CRBRC;
  • A is aryl, arylalkyl, cycloalkyl, or cycloalkylalkyl;
  • Li is -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, or -C(S)N(R 7 )- wherein the left end of the -N(R 7 )C(O)-, -C(O)N(R 7 )-, -N(R 7 )C(S)-, and -C(S)N(R 7 )- is attached to A and the right end is attached to D;
  • L 2 is a bond or alkylene
  • D is alkylene, fluoroalkylene, or hydroxyalkylene
  • R A , RB, Rc, RD, and R E are independently hydrogen or alkyl
  • Ri, R 2 , R 3 , and R 4 are each independently hydrogen, alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )alkyl, (NZ 3 Z 4 )carbonyl, or (NZ 3 Z )sulfonyl;
  • Zi and Z 2 are each independently hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, or formyl;
  • Z 3 and Z are each independently hydrogen, alkyl, aryl, or arylalkyl
  • X is N(Re), O, or S
  • Y is C(R 4 ) orN
  • R 6 is hydrogen or alkyl
  • R 7 is hydrogen or alkyl.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
  • X 2 is CR D R E ;
  • L is -N(R 7 )C(O)-;
  • L 2 , D, R R 2 , R 3 , R A , R 7 , R A , R B , R C , RD, and RE are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nitro, (NZ 3 Z 4 )alkyl, or
  • R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; Xi is CR B R C ; X2 is CR D RE; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R B , Re, RD, and R E are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R ⁇ is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or
  • (NZ 3 Z 4 )carbonyl; R 2 and R 4 are hydrogen; R 3 is hydrogen or hydroxy; X] is CR B Rc; X 2 is CR D R E ; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and R 7 , R A , R B , Rc, R D , and R E are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle; B is
  • RE, R 2 , R 3 , and R are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, pynolyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1 , 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nifro; B is
  • R 2 and R 3 are hydrogen; Xi is CR B Rc; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; and Rg, RA, R B , R C , R D , R E , and R are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
  • R 2 and R 3 are hydrogen; Xi is CR B Rc; 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
  • D is -CH 2 -;
  • L 2 is a bond;
  • L is - ⁇ (R 7 )C(O)-; and
  • R A , R B , Rc, R D , R E , and R 7 are hydrogen; and
  • Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
  • ⁇ 2 is CR D R E ;
  • L is -N(R 7 )C(O)-; and
  • L 2 , D, R h R 2 , R 3 , R 4 , R 7 , R A , R D , and R E are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is Ri is hydrogen, alkyl, cyano, haloalkyl, halogen, nifro, (NZ 3 Z )alkyl, or
  • CRDRE CRDRE
  • D is -CH 2 -
  • L 2 is a bond
  • L is -N(R 7 )C(O)-
  • R 7 , R A , RD, and R E are as defined in formula (IN).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or - ⁇ Z ⁇ Z 2 ; B is
  • R 2 and R 4 are hydrogen;
  • R 3 is hydrogen or hydroxy;
  • Xi is a bond;
  • X 2 is CR D R E ;
  • D is -CH 2 -;
  • L 2 is a bond;
  • L is -N(R )C(O)-;
  • R 7 , R A , R D , and R E are hydrogen.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle; B is
  • Xi is a bond
  • X 2 is CR D RE
  • L is -N(R 7 )C(O)-
  • R 3 , and R 7 are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl, benzothiazolyl, furyl, imidazolyl, 1,3-oxazolyl, pyrazinyl, pyrazolyl, pyridazinyl, pyridinyl, pyrimidinyl, py olyl, 1,3-thiazolyl, or thienyl, wherein the heterocycle is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkoxycarbonyl, alkyl, cyano, halogen, haloalkoxy, haloalkyl, or nitro; B is R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S;
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is heterocycle wherein the heterocycle is benzimidazolyl substituted with 1 alkyl substitutuent wherein a prefened alkyl substituent is methyl; B is
  • R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is N; D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; RA, RD, RE, and R are hydrogen; and Re is hydrogen or alkyl wherein a prefened alkyl is methyl.
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
  • Xi is a bond
  • X 2 is CR D R E
  • L is -N(R 7 )C(O)-
  • D, L 2 , X, Y, R A , R D , RE, R 2 , R 3 , and R 7 are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 2 and R 3 are hydrogen; Xi is a bond; X 2 is CR D R E ; X is N(R 6 ), O, or S; Y is
  • R 4 C(R 4 ); D is -CH 2 -; L 2 is a bond; L is -N(R 7 )C(O)-; R A is hydrogen, alkyl, or cyano; and R5, R A , R D , R E , and R 7 are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZjZ 2 ; B is
  • R 2 and R 3 are hydrogen; X] is a bond; X 2 is CRDRE; X is N(R 6 ), O, or S; Y is
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl; B is
  • X ! is CR B Rc; X 2 is a bond; L is -N(R 7 )C(O)-; and L 2 , D, R R 2 , R 3 , ;, R 5 ,
  • R 7 , RA, RB, and Rc are as defined in formula (TV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nifro, phenyl, or -NZ ⁇ Z 2 ; B is
  • Ri, R 2 , R 3 , ⁇ , and R 5 are hydrogen; Xi is CRBR C ; X 2 is a bond; D is -CH 2 -;
  • L 2 is -CH 2 -; L is -N(R )C(O)-; and R B , Rc, and R 7 are as defined in formula (IV).
  • the present invention relates to a method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) wherein A is aryl wherein the aryl is phenyl substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkenyl, alkoxy, alkoxycarbonyl, alkyl, alkythio, benzyl, cyano, halogen, haloalkoxy, haloalkyl, methylenedioxy, nitro, phenyl, or -NZ ⁇ Z 2 ; B is
  • R 1; R 2 , R 3 , , and R 5 are hydrogen; Xi is CR B R C ; X 2 is a bond; D is -CH 2 -;
  • L 2 is -CH 2 -; L is -N(R 7 )C(O)-; and R B , Rc, and R 7 are hydrogen.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IN) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating male erectile dysfunction in a male human comprising administering to the male human in need of such freatment a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating male erectile dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a pharmaceutically acceptable carrier.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a phosphodiesterase 5 inhibitor.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with an adrenergic receptor antagonist.
  • the present invention relates to method of treating female sexual dysfunction in a mammal comprising administering to the mammal a therapeutically effective amount of a compound of formula (IV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof in combination with a dopamine agonist.
  • the present invention relates to method of treating a disorder wherein the disorder is cardiovascular disorders, inflammatory disorders, attention deficit hyperactivity disorder, Alzheimer's disease, drug abuse, Parkinson's disease, schizophrenia, anxiety, mood disorders or depression in a mammal comprising administering to the mammal in need of such treatment a therapeutically effective amount of a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
  • a compound of formula (TV) or a pharmaceutically acceptable salt, ester, amide, or prodrug thereof.
  • alkenyl as used herein, means a straight or branched chain hydrocarbon containing from 2 to 10 carbons and containing at least one carbon-carbon double bond formed by the removal of two hydrogens.
  • Representative examples of alkenyl include, but are not limited to, ethenyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5- hexenyl, 2-heptenyl, 2-methyl-l-heptenyl, and 3-decenyl.
  • alkoxy as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkoxy include, but are not limited to, methoxy, ethoxy, propoxy, 2-propoxy, butoxy, tert-butoxy, pentyloxy, and hexyloxy.
  • alkoxycarbonyl as used herein, means an alkoxy group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkoxycarbonyl include, but are not limited to, methoxycarbonyl, ethoxycarbonyl, and tert-butoxycarbonyl.
  • alkoxysulfonyl as used herein, means an alkoxy group, as defined herein, appended appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkoxysulfonyl include, but are not limited to, methoxysulfonyl, ethoxysulfonyl and propoxysulfonyl.
  • alkyl as used herein, means a straight or branched chain hydrocarbon containing from 1 to 10 carbon atoms.
  • Representative examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, n- pentyl, isopentyl, neopentyl, n-hexyl, 3-methylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.
  • alkylcarbonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of alkylcarbonyl include, but are not limited to, acetyl, 1-oxopropyl, 2,2-dimethyl- 1-oxopropyl, 1-oxobutyl, and 1-oxopentyl.
  • alkylcarbonyloxy means an alkylcarbonyl group, as defined herein, appended to the parent molecular moiety through an oxygen atom.
  • Representative examples of alkylcarbonyloxy include, but are not limited to, acetyloxy, ethylcarbonyloxy, and tert-butylcarbonyloxy.
  • alkylene means a divalent group derived from a straight or branched chain hydrocarbon of from 1 to 10 carbon atoms. Examples are -CH 2 -, -CH 2 CH 2 -, -CH(CH 3 )-, -CH(CH 2 CH 3 )-, -CH 2 CH 2 CH 2 -, and -CH 2 CH 2 CH 2 CH 2 -.
  • alkylsulfinyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfinyl group, as defined herein.
  • Representative examples of alkylsulfinyl include, but are not limited to, methylsulfinyl and ethylsulfinyl.
  • alkylsulfonyl as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of alkylsulfonyl include, but are not limited to, methylsulfonyl and ethylsulfonyl.
  • alkylthio as used herein, means an alkyl group, as defined herein, appended to the parent molecular moiety through a sulfur atom.
  • Representative examples of alkylthio include, but are not limited, methylsulfanyl, ethylsulfanyl, tert-butylsulfanyl, and hexylsulfanyl.
  • alkynyl as used herein, means a straight or branched chain hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.
  • Representative examples of alkynyl include, but are not limited, to acetylenyl, 1- propynyl, 2-propynyl, 3-butynyl, 2-pentynyl, and 1-butynyl.
  • aryl as used herein, means a phenyl group, or a bicyclic fused ring system, or a tricyclic fused ring system wherein one or more of the fused rings is a phenyl group.
  • Bicyclic fused ring systems are exemplified by a phenyl group fused to another phenyl group or fused to a cycloalkyl group wherein the cycloalkyl group is selected from cyclopentane, cycloahexane, cycloheptane, or cyclooctane.
  • Tricyclic fused ring systems are exemplified by a bicyclic fused ring system fused to a phenyl group.
  • aryl include, but are not limited to, anthracenyl, azulenyl, fluorenyl, 5,6,7,8- tefrahydronaphthalenyl, 5,6,7,8-tefrahydro-l-naphthalenyl, 1,2,3,4-tetrahydro-l-naphthalenyl, ( 1 S)- 1 ,2,3 ,4-tetrahydro- 1 -naphthalenyl, ( 1 R)- 1 ,2,3 ,4-tefrahydro- 1 -naphthalenyl, indanyl, indenyl, ,3-dihydro-lH-indenyl, 2,3-dihydro-lH-inden-5-yl, 1-naphthyl, 2-naphthyl, and phenyl.
  • the aryl groups of the present invention are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, methylenedioxy, nifro, - NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl.
  • substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkyl
  • the aryl groups of this invention can be further substituted with an additional aryl or arylalkyl group, as defined herein, wherein the additional aryl group or the aryl portion of arylalkyl group are substituted with 0, 1, 2, 3, 4, or 5 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, methylenedioxy, nifro, - NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z 4 )sulfonyl.
  • substituents independently selected from alkoxy, alkenyl, alkyl, alkyl
  • Representative examples include, but are not limited to, l,3-benzodioxol-5-yl, 3-benzylphenyl, l,l'-biphenyl-3yl, 2-bromophenyl, 3- bromophenyl, 4-bromophenyl, 4-bromo-3-methylphenyl, 4-bromo-2-methylphenyl, 2- chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 3-chloro-4-fluorophenyl, 4-chloro-3- methoxyphenyl, 3-chloro-2-methylphenyl, 2-chloro-5-methylphenyl, 2-chloro-6- methylphenyl, 4-chloro-2,6-dimethylphenyl, 3-chloro-4-fluorophenyl, 5-chloro-2- methylphenyl, 4-chloro-3-methylphenyl, 3-chloro-4-methylphenyl, 2-chloro-5- trifluoromethylphen
  • arylalkyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of arylalkyl include, but are not limited to, phenylmethyl, 2-phenylethyl, 3- phenylpropyl, and 3-(2-methylphenyl)propyl.
  • arylsulfonyl as used herein, means an aryl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of arylsulfonyl include, but are not limited to, phenylsulfonyl, 2- methylphenylsulfonyl, 2-nitrophenylsulfonyl, and 3-nitrophenylsulfonyl.
  • arylalkylsulfonyl as used herein, means an arylalkyl group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • Representative examples of arylalkylsulfonyl include, but are not limited to, (phenylmethyl)sulfonyl, (2-phenylethyl)sulfonyl, and (3-phenylpropyl)sulfonyl.
  • carbonyl as used herein, means a -C(O)- group.
  • cyano as used herein, means a -CN group.
  • cycloalkyl as used herein, means a monocyclic, bicyclic, or tricyclic ring system.
  • Monocyclic ring systems are exemplified by a saturated cyclic hydrocarbon group containing from 3 to 8 carbon atoms. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Bicyclic ring systems are exemplified by a bridged monocyclic ring system in which two non-adjacent carbon atoms of the monocyclic ring are linked by an alkylene bridge of between one and three additional carbon atoms (-CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -).
  • Representative examples of bicyclic ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, bicyclo[3.3.1]nonane, and bicyclo[4.2.1]nonane.
  • Tricyclic ring systems are exemplified by a bicyclic ring system in which two non-adjacent carbon atoms of the bicyclic ring are linked by a bond or an alkylene bridge of between one and three carbon atoms (-CH 2 -, -CH 2 CH 2 -, and -CH 2 CH 2 CH 2 -).
  • Representative examples of tricyclic-ring systems include, but are not limited to, tricyclo[3.3.1.0 3,7 ]nonane and tricyclo[3.3.1.1 3 ' 7 ]decane (adamantyl).
  • cycloalkyl groups of the present invention are substituted with 0, 1, 2, 3, or 4 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nifro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl or (NZ 3 Z 4 )sulfonyl.
  • substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carb
  • fluoroalkylene means at least one fluoride atom (-F) is appended to the parent molecular moiety through an alkylene group, as defined herein.
  • fluoroalkylene are -CH(F)-, -CH(F)CH 2 -, -C(F) 2 CH 2 -, -CH(F)CH(F)-, -CH(CF 3 )-, -CH(CH 2 CF 3 )-, and -CH 2 CH 2 CH 2 CH(F)-.
  • halo or halogen as used herein, refers to -CI, -Br, -I or -F.
  • haloalkoxy means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkoxy group, as defined herein.
  • Representative examples of haloalkoxy include, but are not limited to, 2-fluoro-l- chloroethoxy, chloromethoxy, 2-fluoroethoxy, frifluoromethoxy, and pentafluoroethoxy.
  • haloalkyl as used herein, means at least one halogen, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of haloalkyl include, but are not limited to, chloromethyl, 2- fluoroethyl, trifluoromethyl, pentafluoroethyl, and 2-chloro-3-fTuoropentyl.
  • heterocycle or “heterocyclic” as used herein, means a monocyclic, bicyclic, or tricyclic ring system.
  • Monocyclic ring systems are exemplified by any 3- or 4- membered ring containing a heteroatom independently selected from oxygen, nitrogen and sulfur; or a 5-, 6- or 7-membered ring containing one, two or three heteroatoms wherein the heteroatoms are independently selected from nitrogen, oxygen and sulfur.
  • the 5-membered ring has from 0-2 double bonds and the 6- and 7-membered ring have from 0-3 double bonds.
  • monocyclic ring systems include, but are not limited to, azetidinyl, azepanyl, aziridinyl, diazepinyl, 1,3-dioxolanyl, dioxanyl, dithianyl, furyl, imidazolyl, imidazolinyl, imidazolidinyl, isothiazolyl, isothiazolinyl, isothiazolidinyl, isoxazolyl, isoxazolinyl, isoxazolidinyl, morpholinyl, oxadiazolyl, oxadiazolinyl, oxadiazolidinyl, oxazolyl, oxazolinyl, oxazolidinyl, piperazinyl, piperidinyl, pyranyl, pyrazinyl, pyrazolyl, pyrazolinyl, pyrazolidinyl, pyridinyl,
  • Bicyclic ring systems are exemplified by any of the above monocyclic ring systems fused to a phenyl group, a cyclohexyl group, a cyclopentyl group, or another monocyclic heterocycle.
  • Representative examples of bicyclic ring systems include but are not limited to, for example, benzimidazolyl, benzodioxinyl, benzothiazolyl, benzothienyl, benzotriazolyl, benzoxazolyl, benzofuranyl, benzopyranyl, benzothiopyranyl, cinnolinyl, indazolyl, indolyl, 2,3-dihydroindolyl, indolizinyl, naphthyridinyl, isobenzofuranyl, isobenzothienyl, isoindolyl, isoquinolinyl, phthalazinyl, pyranopyridinyl, quinolinyl,
  • Tricyclic rings systems are exemplified by any of the above bicyclic ring systems fused to a phenyl group, a cyclohexyl group, a cyclopentyl group, or another monocyclic heterocycle.
  • Representative examples of tricyclic ring systems include, but are not limited to, acridinyl, carbazolyl, carbolinyl, dibenzo[b,d]fixranyl, dibenzo[b,d]thienyl, naphtho[2,3-b]furan, naphtho[2,3-b]thienyl, phenazinyl, phenothiazinyl, phenoxazinyl, thianthrenyl, thioxanthenyl and xanthenyl.
  • heterocycles of this invention are substituted with 0, 1, 2,or 3 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z )carbonyl, and (NZ 3 Z 4 ) sulfonyl.
  • heterocycle groups of this invention can be further substituted with an additional heterocycle group, as defined herein, wherein the additional heterocycle group is substituted with 0, 1, 2, or 3 substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl, alkylcarbonyl, alkylcarbonyloxy, carboxy, cyano, formyl, halogen, haloalkoxy, haloalkyl, hydroxy, hydroxyalkyl, mercapto, nitro, -NZ ⁇ Z 2 , (NZ 3 Z 4 )carbonyl, and (NZ 3 Z )sulfonyl.
  • substituents independently selected from alkoxy, alkenyl, alkyl, alkylsulfinyl, alkylsulfonyl, alkylthio, alkynyl, alkoxycarbonyl,
  • heterocyclealkyl means a heterocycle, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • heterocyclealkyl include, but are not limited to, pyridin-3- ylmethyl, 2-pyrimidin-2-ylpropyl, and 4-pyridin-2-ylpiperazin-l-ylmethyl.
  • heterocyclecarbonyl means a heterocycle, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of heterocyclecarbonyl include, but are not limited to, pyridin-3- ylcarbonyl, quinolin-3-ylcarbonyl, and 4-pyridin-2-ylpiperazin-l-ylmethylcarbonyl.
  • hydroxy as used herein, means an -OH group.
  • hydroxyalkyl as used herein, means at least one hydroxy group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2- hydroxyethyl, 3-hydroxypropyl 2-ethyl-4-hydroxyheptyl and 2,4-dihydroxybutyl.
  • hydroxyalkylene as used herein, means at least one hydroxy group, as defined herein, is appended to the parent molecular moiety through an alkylene group, as defined herein.
  • Representative examples of hydroxyalkylene are -CH 2 CH(OH)CH 2 -, -CH(CH 2 OH)-, -CH(CH 2 CH 2 OH)-, and -CH 2 CH 2 CH(OH)CH 2 -.
  • mercapto as used herein, means a -SH group.
  • methylenedioxy as used herein, means a -OCH 2 O- group wherein the oxygen atoms of the methylenedioxy are attached to the parent molecular moiety through two adjacent carbon atoms.
  • a representative example includes, but is not limited to, 1,3- benzodioxol-5-yl.
  • nitro as used herein, means a - O 2 group.
  • nitrogen protecting group means those groups intended to protect an amino group against undesirable reactions during synthetic procedures. Nitrogen protecting groups comprise carbamates, amides, N-benzyl derivatives, and imine derivatives. Prefened nitrogen protecting groups are acetyl, benzoyl, benzyl, benzyloxycarbonyl (Cbz), formyl, phenylsulfonyl, pivaloyl, tert-butoxycarbonyl (Boc), tert-butylacetyl, trifluoroacetyl, and triphenylmethyl (trityl).
  • Zi and Z 2 are each independently selected from hydrogen, alkyl, alkylcarbonyl, alkylsulfonyl, aryl, arylalkyl, arylalkylsulfonyl, arylsulfonyl, formyl, heterocycle, heterocyclealkyl, and heterocyclealkylcarbonyl.
  • Representative examples of -NZ ⁇ Z 2 include, but are not limited to, amino, methylamino, dimethylamino, acetylamino, (acetyl)(methyl)amino, and (methylsulfonyl)amino.
  • -NZ 3 Z 4 means two groups, Z 3 and Z , which are appended to the parent molecular moiety through a nitrogen atom.
  • Z 3 and Z 4 are each independently selected from hydrogen, alkyl, aryl, or arylalkyl.
  • Representative examples of -NZ 3 Z include, but are not limited to, amino, methylamino, dimethylamino, ethylmethylamino, phenylamino, (phenylmethyl)amino, (2-phenylethyl)amino, (phenyl)(methyl)amino, and diethylamino.
  • (NZ 3 Z )alkyl as used herein, means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through an alkyl group, as defined herein.
  • Representative examples of (NZ 3 Z 4 )alkyl include, but are not limited to, aminomethyl, (dimethylamino)methyl, and (mefhylamino)methyl.
  • (NZ 3 Z 4 )carbonyl means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through a carbonyl group, as defined herein.
  • Representative examples of (NZ 3 Z 4 )carbonyl include, but are not limited to, aminocarbonyl, (methylamino)carbonyl, (dimethylamino)carbonyl, (phenylmethylamino)carbonyl, ((phenyl)(methyl)amino)carbonyl, (phenylamino)carbonyl, (ethylmethylamino)carbonyl, and (diethylamino)carbonyl.
  • (NZ 3 Z 4 )sulfonyl as used herein, means a -NZ 3 Z 4 group, as defined herein, appended to the parent molecular moiety through a sulfonyl group, as defined herein.
  • (NZ 3 Z 4 )sulfonyl include, but are not limited to, aminosulfonyl, (methylamino)sulfonyl, (dimethylamino)sulfonyl, (phenylmethylamino)sulfonyl, ((phenylmethyl)(methyl)amino)sulfonyl, (phenylmethylamino)sulfonyl, (phenylamino)sulfonyl, and (ethylmethylamino)sulfonyl.
  • sulfinyl as used herein, means a -S(O)- group.
  • sulfonyl as used herein, means a -S(O) 2 - group.
  • sexual dysfunction means sexual dysfunction in mammals including human male and human female sexual dysfunction.
  • male sexual dysfunction includes, but is not limited to, male erectile dysfunction or premature ejacualtion.
  • female sexual dysfunction as used herein includes, but is not limited to, female anorgasmia, clitoral erectile insufficiency, vaginal engorgement, dyspareunia, or vaginismus.
  • Stereoisomers may exist as stereoisomers wherein, asymmetric or chiral centers are present. These stereoisomers are “R” or “S” depending on the configuration of substituents around the chiral carbon atom.
  • R and “S” used herein are configurations as defined in IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem., 1976, 45: 13-30.
  • Stereoisomers include enantiomers and diastereomers, and mixtures of enantiomers or diastereomers.
  • stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (IV) wherein Xi is a bond and X 2 is CR D R E may independently be either (R) or (S).
  • the stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (TV) wherein Xj is CR ⁇ Rc and X 2 is a bond may independently be either (R) or (S).
  • the stereochemistry at the point of attachment of -L 2 -B of compounds of formula (III) or formula (IN) wherein Xi is CR B Rc and X 2 is CR D R E may independently be either (R) or (S).
  • Individual stereoisomers of compounds of the present invention may be prepared synthetically from commercially available starting materials which contain asymmetric or chiral centers or by preparation of racemic mixtures followed by resolution well-known to those of ordinary skill in the art. These methods of resolution are exemplified by (1) attachment of a mixture of enantiomers to a chiral auxiliary, separation of the resulting mixture of diastereomers by recrystallization or chromatography and liberation of the optically pure product from the auxiliary, (2) direct separation of the mixture of optical enantiomers on chiral chromatographic columns, or (3) formation of a diastereomeric salt followed by selective recrystallization of one of the diastereomeric salts.
  • Prefened compounds of the present invention include:
EP03755402A 2002-05-23 2003-05-19 Acetamides and benzamides that are useful in treating sexual dysfunction Withdrawn EP1509213A2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US425152 1982-09-30
US154373 1998-09-16
US10/154,373 US20030232836A1 (en) 2002-05-23 2002-05-23 Acetamides and benzamides that are useful in treating sexual dysfunction
US10/425,152 US20040029887A1 (en) 2002-05-23 2003-04-29 Acetamides and benzamides that are useful in treating sexual dysfunction
PCT/US2003/015868 WO2003099266A2 (en) 2002-05-23 2003-05-19 Acetamides and benzamides that are useful in treating sexual dysfunction

Publications (1)

Publication Number Publication Date
EP1509213A2 true EP1509213A2 (en) 2005-03-02

Family

ID=52340037

Family Applications (1)

Application Number Title Priority Date Filing Date
EP03755402A Withdrawn EP1509213A2 (en) 2002-05-23 2003-05-19 Acetamides and benzamides that are useful in treating sexual dysfunction

Country Status (7)

Country Link
EP (1) EP1509213A2 (pt)
JP (1) JP2005531571A (pt)
AU (1) AU2003231801A1 (pt)
BR (1) BR0306625A (pt)
CA (1) CA2486564A1 (pt)
MX (1) MXPA04011621A (pt)
TW (1) TW200404539A (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4866610B2 (ja) * 2003-08-18 2012-02-01 富士フイルムファインケミカルズ株式会社 ピリジルテトラヒドロピリジン類およびピリジルピペリジン類
WO2010013849A1 (ja) * 2008-08-01 2010-02-04 日本ケミファ株式会社 Ｇｐｒ１１９作動薬

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA825719B (en) * 1981-09-03 1983-06-29 Recordati Chem Pharm Alkanoylanilides
JPS6147466A (ja) * 1984-08-10 1986-03-07 Dainippon Pharmaceut Co Ltd アミン誘導体
FR2573075B1 (fr) * 1984-09-14 1987-03-20 Innothera Lab Sa Nouvelles (pyridyl-2)-1 piperazines, leur procede de preparation et leur application en therapeutique
CA1340113C (en) * 1988-05-24 1998-11-03 Magid A. Abou-Gharbia Aryl-and heteroaryl piperazinyl carboxamides having central nervous system activity
US5395835A (en) * 1994-03-24 1995-03-07 Warner-Lambert Company Naphthalamides as central nervous system agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
AU727972B2 (en) * 1996-05-16 2001-01-04 H. Lundbeck A/S Dihydropyrimidines and uses thereof
AU6230698A (en) * 1997-02-26 1998-09-18 Sumitomo Pharmaceuticals Company, Limited Dopamine d4 receptor antagonist
EP1177172A1 (en) * 1999-05-05 2002-02-06 Ortho-McNeil Pharmaceutical, Inc. 3a,4,5,9b-TETRAHYDRO-1H-BENZ e]INDOL-2-YL AMINE-DERIVED NEUROPEPTIDE Y RECEPTORS LIGANDS USEFUL IN THE TREATMENT OF OBESITY AND OTHER DISORDERS
AR030676A1 (es) * 1999-07-28 2003-09-03 Ortho Mcneil Pharm Inc Derivados de aminas y amidas como ligandos para el receptor del neuropeptido y y5 utiles en el tratamiento de la obesidad y otros trastornos, uso de los mismos para la elaboracion de medicamentos y composiciones farmaceuticas que los comprenden
WO2002041894A2 (en) * 2000-11-22 2002-05-30 Abbott Laboratories Selective dopamine d4 receptor agonists for treating sexual dysfunction
GB0209715D0 (en) * 2002-04-27 2002-06-05 Astrazeneca Ab Chemical compounds

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03099266A2 *

Also Published As

Publication number Publication date
AU2003231801A1 (en) 2003-12-12
BR0306625A (pt) 2006-04-18
TW200404539A (en) 2004-04-01
CA2486564A1 (en) 2003-12-04
AU2003231801A8 (en) 2003-12-12
JP2005531571A (ja) 2005-10-20
MXPA04011621A (es) 2005-03-31

Similar Documents

Publication Publication Date Title
US7528134B2 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
KR102438302B1 (ko) 리신 특이적 데메틸라제-1의 억제제
AU2004253649B2 (en) Thiazolylpiperidine derivatives as MTP inhibitors
KR100970294B1 (ko) 복소환 화합물
EP2456440B1 (en) Quinolinone pde2 inhibitors
US20090069340A1 (en) Pyrazolone Compounds As Metabotropic Glutamate Receptor Agonists For The Treatment Of Neurological And Psychiatric Disorders
US20040029887A1 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
WO2002055496A1 (en) Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
CA2650914A1 (en) Compounds that are agonists of muscarinic receptors and that may be effective in treating pain, alzheimer's disease and/or schizophrenia
AU2005267930A1 (en) Novel piperidine derivative for the treatment of depression
TW201028408A (en) Compounds
JP2009520791A (ja) 酵素阻害剤
ZA200205181B (en) Substituted piperidines, medicaments containing these compounds, and methods for the production thereof.
AU2002303128B2 (en) Benzimidazoles that are useful in treating sexual dysfunction
MX2014015691A (es) Derivados de 1- [m-carboxamido (hetero) aril-metil]-heterociclil-c arboxamida.
US20060009461A1 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
AU2002303128A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
US7470691B2 (en) Fused bicyclic aromatic compounds that are useful in treating sexual dysfunction
CA2538381A1 (en) 3-heterocyclyl-indole derivatives as inhibitors of glycogen synthase kinase-3 (gsk-3)
US20070105893A1 (en) Novel Compounds
EP1483258A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
EP1509213A2 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
US20030232836A1 (en) Acetamides and benzamides that are useful in treating sexual dysfunction
US20040110766A1 (en) Benzimidazoles that are useful in treating sexual dysfunction
CA2172163A1 (en) Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20041221

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK

DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1074781

Country of ref document: HK

RIN1 Information on inventor provided before grant (corrected)

Inventor name: ZHANG, HENRY, Q.

Inventor name: XIA, ZHIREN

Inventor name: WANG, XUEQING

Inventor name: STEWART, ANDREW, O.

Inventor name: PATEL, MEENA, V.

Inventor name: MORTELL, KATHLEEN, H.

Inventor name: MATULENKO, MARK, A.

Inventor name: KOLASA, TEODOZYJ

Inventor name: HAKEEM, AHMED, A.

Inventor name: DAANEN, JEROME, F.

Inventor name: BHATIA, PRAMILA, A.

17Q First examination report despatched

Effective date: 20070221

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100323

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1074781

Country of ref document: HK